Direct costs of opioid abuse in an insured population in the United States.
about
Individual and county-level factors associated with use of multiple prescribers and multiple pharmacies to obtain opioid prescriptions in CaliforniaChanges in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data.Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone.Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: mathematical modeling using a database of commercially-insured individualsImpact of research network participation on the adoption of buprenorphine for substance abuse treatment.Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs.Genetics of Opioid Dependence: A Review of the Genetic Contribution to Opioid Dependence.Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan.Prescription opioid abuse: a literature review of the clinical and economic burden in the United States.Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.A Comparison of Daily Average Consumption Of Oxycodone Controlled Release (OxyContin CR) And Oxymorphone Extended Release (Opana ER) In Patients With Low Back Pain.Managing Opioid Use Disorder During and After Acute Hospitalization: A Case-Based Review Clarifying Methadone Regulation for Acute Care Settings."I'm not afraid of those ones just 'cause they've been prescribed": perceptions of risk among illicit users of pharmaceutical opioids.A Review of Potential Adverse Effects of Long-Term Opioid Therapy: A Practitioner's GuideNew Perspectives in the Treatment of Opioid-Induced Respiratory Depression.Risk based in vitro performance assessment of extended release abuse deterrent formulationsLigand interaction, binding site and G protein activation of the mu opioid receptorProbability and predictors of treatment-seeking for prescription opioid use disorders: a national study.Adoption of medications in substance abuse treatment: priorities and strategies of single state authoritiesPrescription opioid abuse: challenges and opportunities for payers.Can abuse deterrent formulations make a difference? Expectation and speculation.Issues in long-term opioid therapy: unmet needs, risks, and solutions.A Tool for Assessing a Community's Capacity for Substance Abuse Care.Development and preliminary validation of the Opioid Abuse Risk Screener.Predisposing effects of neonatal visceral pain on abuse-related effects of morphine in adult male Sprague Dawley ratsLessons learned in the abuse of pain-relief medication: a focus on healthcare costs.Changes in the medical management of patients on opioid analgesics following a diagnosis of substance abuse.Experience with an extended-release opioid formulation designed to reduce abuse liability in a community-based pain management clinic.Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: A pilot randomized controlled trial.Cost drivers of prescription opioid abuse in commercial and Medicare populations.Reducing Disability Durations and Medical Costs for Patients With a Carpal Tunnel Release Surgery Through the Use of Opioid Prescribing Guidelines.Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study.Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorderCorrelates of Non-Medical Prescription Drug Misuse Among a Treatment-Seeking Population: A Comparison with Illicit Drug Users
P2860
Q28483999-ED4C9C86-1372-48C9-BD78-A81D2FA2105BQ30677208-F20C7049-3FF0-4DA7-9D89-11A37892B0B1Q30830475-EDBF3361-892A-41E5-B92F-813C108A3D52Q31131823-5E1F2956-D882-42FD-9012-B2BA47DF5A53Q33716509-0B234565-4626-454F-BA52-7D70EC50908AQ33776944-8AD1B222-9AE0-4E99-925B-5A623FFFE091Q33932344-A7A16579-8D9B-4537-A6F5-499123891EFAQ34139876-12E5DF95-97B4-4001-AB90-EA3A65447ED6Q34176572-42524EB6-4F67-4E7B-BB9A-2465A756127CQ34751280-0732F73D-492A-4685-BF18-4F0DB5DAEF7BQ34808676-3A7F0BB1-8ACD-45EE-B8D2-C85E89455AC9Q34906485-9958BB3C-3832-432C-BDEE-A24DED85239EQ35923117-E94C35CA-4985-43AA-B0EA-42F96C1F94CCQ36070144-67223E2E-A9A7-45AA-A8CD-15E3561FF76AQ36302851-9B71434D-3CC2-4A91-9CE3-6AFD372866F6Q36333862-B8C60ED8-01F9-494A-821E-21C4F6BC4D9FQ36586105-5ED27A52-3439-4004-B444-906DE7609B55Q36717977-A865B3E9-BD36-49CF-9913-5CD1941BFB91Q36794523-37CEDA6C-9565-43C5-9FE3-977B246178ADQ36806539-51365EBE-C1DB-4342-967A-AB5B08BA6E85Q36922546-3CAAF1F0-AFDB-4FB6-8E89-6E964DB04DC3Q37223480-CEF57979-0A94-47EA-865D-E8A5FDDE41E4Q37246241-5C03E085-80FC-42F6-995F-5B6593D943A6Q37278748-0FC30787-6E26-49FA-9956-AB9E47813618Q37540584-61DA5216-4D32-4FAD-A49E-B7787FBD3C5FQ37741405-F83601FF-9C0C-4DB5-93C1-8CFF2364BD40Q38101985-097D55C0-A5DC-44BC-BB47-94056D381C5DQ38727754-6F18CFF9-1C27-4B75-A062-DC6247494B3FQ38905036-B1D399DF-C0DB-4A8F-B038-4FAAB856BA3BQ44137641-5048D671-E240-4DFF-BBF4-4E1DF769AC9CQ44342152-C95C1D8C-1538-48B8-A576-38E62147DCA7Q44349116-06011B2C-427A-4799-B6E4-354AC28A022EQ55225065-5105969C-4FAB-4A92-A4AF-D95AC2AF4846Q57492671-E7A00221-DE3D-45AB-9085-A66249CA18D1Q58749520-95CCA8F1-E72F-45D9-8C30-D1CBF8D43C3B
P2860
Direct costs of opioid abuse in an insured population in the United States.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Direct costs of opioid abuse in an insured population in the United States.
@ast
Direct costs of opioid abuse in an insured population in the United States.
@en
type
label
Direct costs of opioid abuse in an insured population in the United States.
@ast
Direct costs of opioid abuse in an insured population in the United States.
@en
prefLabel
Direct costs of opioid abuse in an insured population in the United States.
@ast
Direct costs of opioid abuse in an insured population in the United States.
@en
P2093
P1476
Direct costs of opioid abuse in an insured population in the United States.
@en
P2093
Alan G White
Howard G Birnbaum
Jeff Schein
Maham Daher
Milena N Mareva
Nathaniel Katz
Susan Vallow
P304
P356
10.18553/JMCP.2005.11.6.469
P577
2005-07-01T00:00:00Z